Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized controlled study of LNS8801 alone or in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma

Next Previous
Search
Trial Profile

Randomized controlled study of LNS8801 alone or in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 26 Mar 2025 According to Linnaeus Therapeutics media release, $2,000,000 Direct-to-Phase 2 Award Funds Study of LNS8801 in the Treatment of Melanoma.
  • 20 Mar 2025 Planned number of patients changed to 135.
  • 20 Mar 2025 According to Linnaeus Therapeutics media release, company anticipates initiating this clinical trial this year.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top